It is not known whether topical ocular treatment with LATISSE 0.03% could result in sufficient systemic absorption to produce detectable quantities in human milk. In animal studies, bimatoprost has been shown to be present in milk of lactating rats at an intravenous dose (i.e., 1 mg/kg) 324 times the recommended human ophthalmic dose (on a mg/m2 basis), however no animal data is available at clinically relevant doses.
The developmental and health benefits of chestfeeding should be considered along with the parent's clinical need for LATISSE 0.03% and any potential adverse effects on the chestfed child from LATISSE 0.03%.
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34f83d9d-2c64-463e-8a90-9a460fedfead